H. KAZANCIOĞLU, Merve ERİŞEN, Nihat DEMİRTAŞ, Aydın TÜRKMEN, Gülsüm AK

DİŞ ETİ BÜYÜMESİ MEYDANA GETİREN İLAÇLAR VE TEDAVİLERİ

Fenitoin tedavisine bağlı olarak oluşan diş eti büyümesi ilk olarak 1939 yılında Kimball tarafından rapor edilmiştir. Günümüzde, siklosporin ve kalsiyum kanal blokerlerinin diş eti büyümesi ile ilişkili olduğu bilinmektedir. İlaca bağlı diş eti büyümelerinin nedeni tam olarak açığa kavuşturulamasa da, multi-faktöriyel olduğu açıktır. Diş eti enflamasyonu, dental plak varlığı, periodontal cep derinliği, siklosporin tedavisinin dozu ve süresi gibi bazı etkenlerin risk faktörü olduğu ve diş eti büyümesini tetiklediği düşünülmektedir. Diş eti büyümesi olan hastalar, siklosporin, fenitoin veya kalsiyum kanal blokeri tedavisi aldığı sürece, medikal tedaviye bağlı gelişen komplikasyonların değerlendirilmesi ve tedavisi için bir ağız hastalıkları ve periodontoloji uzmanı tarafından izlenmelidirler.

Anahtar Kelimeler:

Diş eti büyümesi, siklosporin, fenitoin, kalsiyum kanal blokeri

-

Gingival overgrowth (GO) that associated with phenytoin tharapy was first reported in the dental literature in 1939 by Kimball. Recently, cyclosporine and numerous calcium channel blocker agents have been associated with GO. The etiology of drug-induced GO is not entirely understood but is clearly multifactorial. Some of the risk factors known to contribute to GO include the presence of gingival inflammation, presence of dental plaque, the depth of the periodontal pocket on probing, and the dose and duration of cyclosporine therapy. An oral medicine specialist and a periodontist should monitor patients with GO for as long as they receive therapy with cyclosporine, phenytoin, or calcium channel blockers to evaluate and treat oral complications from medical therapy.

Keywords:

Gingival overgroth, cyclosporine, phenytoin, calcium channel blockers,

PDF

___

Kimball OP. The treatment of epilepsy with sodium diphenyl hyantoinate, JAMA, 1939; 112: 1244-45. Dongari AI, Langlais RP, McDonnell HT. Drug-induced gingival overgrowth. Oral Surg Oral Med Oral Pathol, 1993; 76: 543Hallmon WW, Rossmann JA. The role of drugs in the pathogenesis of gingival overgrowth. A collective review of current concepts. Periodontol 2000, 1999; 21: 176-96. Katz J, Givol N, Chaushu G, Taicher S, Shemer J. Vigabatrin- induced gingival overgrowth. J Clin Periodontol, 1997; 24: 180- Barak S, Engelberg I, Hiss Z. Gingival hyperplasia caused by nifedipine: histopathological findings. J Periodontol, 1987; 58: 639- Nakou M, Kamma JJ, Andronikaki A, Mitsis F. Subgingival microflora associated with nifedipine-induced gingival overgrowth. J Periodontol, 1998; 69: 664-69. Rateitschak-Pluss E, Hefti A, Lortscher R, Thiel G. Initial observation that cyclosporin-A induces gingival enlargement in man. J Clin Periodontol, 1983; 10: 237-46. Thomas DW, Newcombe RG, Osborne GR. Risk factors in the development of cyclosporine-induced gingival overgrowth. Transplantation, 2000; 69: 522-26. Anderson HH, Rapley JW, Williams DR. Gingival overgrowth with valproic acid: a case report. ASDC J Dent Child, 1997; 64(4): 294-97.
Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: a community based study. J Periodontol, 1999; 70: 63-67. Boltchi FE, Rees TD, Iacopino AM.
Cyclosporine a-induced gingival overgrowth: a comprehensive review. Quintessence Int, 1999; 30: 775-83. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol, 1999; 4: 1-6. Fattore L, Stablein M, Bredfelt G, et al. Gingival hyperplasia: a side effect of nifedipine and diltiazem. Spec Care Dent, 1991; 11: 107-09. Myers BD, Newton L. Cyclosporineinduced chronic nephropathy: an obliterative microvascular renal injury. J Am Soc
Nephrol, 1991; 2(1): 45-52. Dongari-Bagtzoglou A, Research
Science and Therapy Committee, American Academy of Periodontology. Drug-associated gingival enlargement. Informational paper. J Periodontol, 2004; 75(10): 1424-31. Butler RT, Kalkwarf KL, Kadhal WB.
Drug-induced gingival hyperplasia: phenytoin, cyclosporine and nifedipine. JADA, 1987; 114: 55-60. Ciancio S, Bartz N, Lauciello F. Cyclosporine-induced gingival hyperplasia and chlorhexidine: a case report. Int J Periodontics Restorative Dent, 1991; 11: 241-45. Hernandez G, Arriba L, Lucas M, Andres A. Reduction of severe gingival overgrowth in a kidney transplant patient by replacing cyclosporin a with tacrolimus.
J Periodontol, 2000; 71: 1630-36. İlgenli T, Atilla G, Baylas H. Effectiveness of periodontal therapy in patients with drug-induced gingival overgrowth.
Long term results. J Periodontol, 1999; 70: 967James JA, Jamal S, Hull PS, Macfarlane TV, Campbell BA, Johnson RWG, Short CG: Tacrolimus is not associated with gingival overgrowth in renal transplant patients. J Clin Periodontol, 2001; 28: 848-52. Kantarcı A, Cebeci İ, Tuncer Ö, Çarın M, Fıratlı E. Clinical effects of periodontal therapy on the severity of cyclosporin: ainduced gingival hyperplasia. J Periodontol, 1999; 70: 587-93.
Wong W, Hodge MG, Lewis A, Sharpstone P, Kingswood JC. Resolution of cyclosporin-induced gingival hypertrophy with metronidazole. The Lancet, 1994; 343: 86. Seymour RA, Smith DG, Rogers SR. The comparative effects of azathioprine and cyclosporin on some gingival health parameters of renal transplant patients. J Clin Periodontol, 1987; 14: 610-13.
Pick RM, Colvard MD. Current status of lasers in soft tissue dental surgery. Review. J Periodontol, 1993; 64: 589-602.
Seymour RA, Smith DG. The effect of a plaque control programme on the incidence and severity of cyclosporin-induced gingival changes. J Clin Periodontol, 1991; 18: 107-10. Yazışma Adresi: H. Oğuz KAZANCIOĞLU
Bezmialem Üniversitesi Diş hekimliği Fakültesi Ağız Diş Çene Hastalıkları ve Cerrahisi A.D. Fatih / İstanbul Tel: (212) 523 37 19 - (212) 453 17 00 e-posta: dt_oguz@yahoo.com